🔎 Trials Near Me

Почетна › Akutna mijeloidna leukemija › Охајо

Kliničke studije za Akutna mijeloidna leukemija u državi Охајо

56 studija za Akutna mijeloidna leukemija traži učesnike na lokacijama u državi Охајо.

Gradovi u državi Охајо

Zvanični tekst studije (na engleskom)

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

  • Case Western Reserve University, Cleveland
  • Ohio State University Comprehensive Cancer Center, Columbus
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT06317649

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

  • Ohio State University, Columbus
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT07007312

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

  • Case Western Reserve University, Cleveland
  • Ohio State University Comprehensive Cancer Center, Columbus
Тражи се учесникФаза 2
Узраст од 18 до 59 · Оба пола · Ажурирано 9. 11. 2026. · NCT05554406

Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy

  • Ohio State University Comprehensive Cancer Center, Columbus
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 9. 11. 2026. · NCT06930352

HPC Offered for PRESERVE Expansion

  • The Ohio State University Medical Center, Columbus
Тражи се учесникОпсервациона студија
Узраст од 12 до 80 · Оба пола · Ажурирано 6. 11. 2026. · NCT07145411

Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

  • US-Cincinnati OH-CINCY, Cincinnati
  • US-Colombus OH-OSU, Columbus
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 6. 11. 2026. · NCT07223814

Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

  • Ohio State University Comprehensive Cancer Center, Columbus
Тражи се учесникФаза 2
Узраст 60 и старији · Оба пола · Ажурирано 6. 11. 2026. · NCT07437950

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Summa Health System - Akron Campus, Akron
  • Cleveland Clinic Akron General, Akron
  • Summa Health System - Barberton Campus, Barberton
  • и још 44
Тражи се учесникОпсервациона студијаЗдраве особе су добродошле
Узраст од 40 до 75 · Оба пола · Ажурирано 4. 11. 2026. · NCT05334069

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

  • Gabrail Cancer Center, Canton
  • Miami Valley Hospital South, Centerville
  • Oncology Hematology Care, Cincinnati
  • и још 2
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT06852222

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

  • Case Western Reserve University, Cleveland
  • Ohio State University Comprehensive Cancer Center, Columbus
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 2. 11. 2026. · NCT05564390

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

  • University of Cincinnati Medical Center (University Hospital), Cincinnati
  • The Ohio State University Comprehensive Cancer Center (OSUCCC), Cleveland
Тражи се учесникФаза 3
Узраст од 18 до 75 · Оба пола · Ажурирано 30. 10. 2026. · NCT05429632

Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring

  • Cleveland Clinic Mercy Hospital, Canton
  • University Hospitals Seidman Cancer Center, Cleveland
  • Tri-County Hematology & Oncology Associates, Inc., Massillon
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 30. 10. 2026. · NCT05974150

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

  • Cincinnati Children's Hospital Medical Center, Cincinnati
Тражи се учесникОпсервациона студија
Узраст од 0 до 38 · Оба пола · Ажурирано 29. 10. 2026. · NCT06131801

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

  • Case Western Reserve University, Cleveland
Тражи се учесникФаза 2
Узраст од 18 до 59 · Оба пола · Ажурирано 28. 10. 2026. · NCT05554393

A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)

  • The Ohio Sate University, Columbus
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 23. 10. 2026. · NCT06969430

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

  • Cincinnati Children's Hospital Medical Center, Cincinnati
Тражи се учесникФаза 1
До 21 година · Оба пола · Ажурирано 23. 10. 2026. · NCT07012044

Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

  • Cincinnati Children's Hospital Medical Center, Cincinnati
Тражи се учесникФаза 1
Узраст од 1 до 30 · Оба пола · Ажурирано 22. 10. 2026. · NCT06177067

Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML/HR-MDS and in Combination With Azacitidine in Previously Untreated HR-MDS

  • Cleveland Clinic, Cleveland
  • Ohio State University, Columbus
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 20. 10. 2026. · NCT06533761

Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant

  • Cleveland Clinic Cancer Center, Cleveland
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 20. 10. 2026. · NCT06543381

Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS

  • Ohio State University, The James Comprehensive Cancer, Columbus
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 16. 10. 2026. · NCT06846606

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

  • Ohio State University, Columbus
Тражи се учесникФаза 1/2
30 Days · Оба пола · Ажурирано 9. 10. 2026. · NCT04065399

A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies

  • University of Cincinnati, Cincinnati
  • OhioHealth Research Institute, Columbus
  • Taylor Cancer Research Center, Maumee
Тражи се учесникОпсервациона студија
Узраст 0 и старији · Оба пола · Ажурирано 9. 10. 2026. · NCT07154823

Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant

  • Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center, Cleveland
  • University Hospitals Seidman Cancer, Case Comprehensive Cancer Center, Cleveland
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 8. 10. 2026. · NCT06129734

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

  • Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute, Columbus
Тражи се учесникФаза 2/3
Узраст 18 и старији · Оба пола · Ажурирано 6. 10. 2026. · NCT04256317

Ziftomenib Maintenance Post Allo-HCT

  • Ohio State University Wexner Medical Center- James Cancer Hospital, Columbus
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 6. 10. 2026. · NCT06440135

Ivosidenib as Post-HSCT Maintenance for AML

  • Ohio State University Wexner Medical Center- James Cancer Hospital, Columbus
Тражи се учесникФаза 2
Узраст од 18 до 75 · Оба пола · Ажурирано 5. 10. 2026. · NCT06707493

Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

  • Ohio State University Comprehensive Cancer Center, Columbus
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 24. 9. 2026. · NCT03874052

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

  • Children's Hospital Medical Center of Akron, Akron
  • Cincinnati Children's Hospital Medical Center, Cincinnati
  • Rainbow Babies and Childrens Hospital, Cleveland
  • и још 4
Тражи се учесникФаза 3
6 Months – 21 Years · Оба пола · Ажурирано 17. 9. 2026. · NCT04293562

Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood

  • Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center Seidman Cancer Center, Cleveland
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 15. 9. 2026. · NCT06904482

Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

  • Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 14. 9. 2026. · NCT03471260

Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction

  • Ohio State University Comprehensive Cancer Center, Columbus
Тражи се учесникФаза 1/2
Узраст од 18 до 75 · Оба пола · Ажурирано 9. 9. 2026. · NCT04049539

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

  • Rainbow Babies and Childrens Hospital, Cleveland
  • ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital, Toledo
Тражи се учесникФаза 3
Узраст од 1 до 25 · Оба пола · Ажурирано 4. 9. 2026. · NCT07022678

Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

  • US-Cincinnati OH-CINCY, Cincinnati
  • US-Colombus OH-OSU, Columbus
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 2. 9. 2026. · NCT06652438

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • Children's Hospital Medical Center of Akron, Akron
  • Cincinnati Children's Hospital Medical Center, Cincinnati
  • Rainbow Babies and Childrens Hospital, Cleveland
  • и још 3
Тражи се учесникФаза 1/2
До 22 година · Оба пола · Ажурирано 25. 8. 2026. · NCT04726241

A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease

  • University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
  • Ohio State University Comprehensive Cancer Center, Columbus
  • University of Cincinnati Cancer Center-West Chester, West Chester
Тражи се учесникФаза 1
Узраст од 18 до 75 · Оба пола · Ажурирано 25. 8. 2026. · NCT05886049

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

  • UH Seidman Cancer Center, Cleveland
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 20. 8. 2026. · NCT06001788

L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML

  • University Hospitals Cleveland Medical Center, Cleveland
Тражи се учесникФаза 2/3
Узраст од 18 до 80 · Оба пола · Ажурирано 5. 8. 2026. · NCT06788756

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

  • Childrens Hospital Medical Center of Akron, Akron
  • Cincinnati Children's Hospital, Cincinnati
  • University Hospitals Case Medical Center, Cleveland
  • и још 3
Тражи се учесникОпсервациона студија
Сви узрасти · Оба пола · Ажурирано 6. 7. 2026. · NCT01351545

IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)

  • Ohio State University Comprehensive Cancer Center, Columbus
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 23. 6. 2026. · NCT05401097

A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)

  • Case Western Reserve University, Cleveland
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 12. 6. 2026. · NCT05834244

Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.